Eugene J. Zurlo

Biography

 Appointed Chairman of the SAB, Zurlo, the inventor of PlasmaTech’s fractionation process, was an executive of Baxter Laboratories, including five years as Sr. Vice-President of its Hyland Division, where he had responsibility for fractionation operations, including development of the process for producing the first commercial AHF concentrate (Hemofil). Subsequently he was Sr. Vice-President of Millipore Corporation, (which developed diafiltration and nanofiltration) and Chief Operating Officer of the New York Blood Center, Inc., when he led the development and licensing of the Solvent-Detergent Method for inactivating lipid-enveloped viruses. He then founded Alpine Biologics Inc., which sourced Recovered Plasma for the Central Laboratory of the Swiss Red Cross and Octapharma Inc. and in return marketed their plasma biologics in the United States. Mr. Zurlo, who is listed on 5 patents as an inventor, is the lead inventor of the Plasma Technologies plasma process technology.

Research Interest

 Plasma Technologies